(CLOI) VanEck Trust - VanEck CLO - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US92189H7483 • Ultrashort Bond
CLOI: Debt, Securities, CLOs, Bonds
The VanEck CLO ETF (NYSE ARCA: CLOI) is an actively managed exchange-traded fund designed to provide exposure to investment-grade-rated debt tranches of collateralized loan obligations (CLOs). The fund typically allocates at least 80% of its total assets to these securities, which are primarily U.S. dollar-denominated. However, it retains the flexibility to invest up to 30% of its net assets in foreign currency-denominated CLO securities, allowing for geographic diversification when opportunities arise. As a non-diversified fund, it can concentrate its holdings in a smaller number of securities, which may amplify both potential returns and risks.
With over $939 million in assets under management (AUM), the fund is part of VanEcks lineup of specialized fixed-income ETFs. It focuses on the upper tranche of the CLO capital structure, which is typically senior and secured, offering a higher level of credit protection compared to lower tranches. This structure makes it appealing to investors seeking exposure to leveraged loans while mitigating some of the associated risks. The funds active management approach allows the portfolio team to selectively invest in CLOs, aiming to optimize yields and navigate the complexities of the CLO market.
Looking ahead, the outlook for the CLO market—and by extension, the VanEck CLO ETF—will likely be shaped by several key factors. The health of the leveraged loan market, which underpins CLOs, will remain critical. As interest rates continue to rise, the floating-rate nature of CLOs may become more attractive to investors seeking to offset inflation and higher borrowing costs. However, the ability of heavily leveraged companies to service their debt will be a key risk factor, particularly in a tighter monetary policy environment. Additionally, regulatory scrutiny of CLOs and the broader structured finance market could influence demand and pricing. Overall, while the CLO market faces challenges, its resilience in past credit cycles and the funds focus on higher-quality tranches position it as a potential stabilizing force in investor portfolios.
Additional Sources for CLOI ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CLOI ETF Overview
Market Cap in USD | 1,021m |
Category | Ultrashort Bond |
TER | 0.40% |
IPO / Inception | 2022-06-21 |
CLOI ETF Ratings
Growth 5y | 43.9% |
Fundamental | - |
Dividend | 76.6% |
Rel. Strength Industry | 8.89 |
Analysts | - |
Fair Price Momentum | 54.29 USD |
Fair Price DCF | - |
CLOI Dividends
Dividend Yield 12m | 6.16% |
Yield on Cost 5y | 7.42% |
Annual Growth 5y | 46.42% |
Payout Consistency | 100.0% |
CLOI Growth Ratios
Growth Correlation 3m | 99% |
Growth Correlation 12m | 99.9% |
Growth Correlation 5y | 99.6% |
CAGR 5y | 7.72% |
CAGR/Max DD 5y | 0.00 |
Sharpe Ratio 12m | 1.06 |
Alpha | 3.12 |
Beta | 0.02 |
Volatility | 1.07% |
Current Volume | 307.9k |
Average Volume 20d | 258k |
As of March 13, 2025, the stock is trading at USD 52.89 with a total of 307,867 shares traded.
Over the past week, the price has changed by -0.04%, over one month by +0.17%, over three months by +1.42% and over the past year by +7.41%.
Partly, yes. Based on ValueRay Analyses, VanEck Trust - VanEck CLO (NYSE ARCA:CLOI) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 43.93 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLOI as of March 2025 is 54.29. This means that CLOI is currently overvalued and has a potential downside of 2.65%.
VanEck Trust - VanEck CLO has no consensus analysts rating.
According to ValueRays Forecast Model, CLOI VanEck Trust - VanEck CLO will be worth about 58.6 in March 2026. The stock is currently trading at 52.89. This means that the stock has a potential upside of +10.85%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 58.6 | 10.9% |